Breast-conserving treatment after neoadjuvant chemotherapy in large breast cancer

被引：35

作者：

Inaji H. ^{[1
]}

Komoike Y. ^{[1
]}

Motomura K. ^{[1
]}

Kasugai T. ^{[2
]}

Sawai Y. ^{[3
]}

Koizumi M. ^{[4
]}

Nose T. ^{[4
]}

Koyama H. ^{[1
]}

机构：

[1] Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Higashinari-ku, Osaka 537-8511

[2] Department of Pathology, Osaka Medical Center for Cancer and Cardiovascular Diseases

[3] Department of Diagnostic Radiology, Osaka Medical Center for Cancer and Cardiovascular Diseases

[4] Department of Radiation Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseases

来源：

Breast Cancer | 2002年 / 9卷 / 1期

关键词：

Breast cancer; Breast-conserving treatment; Local recurrence; Neoadjuvant chemotherapy;

D O I：

10.1007/BF02967542

中图分类号：

学科分类号：

摘要：

Several recent trials have demonstrated that neoadjuvant chemotherapy can allow more patients to successfully undergo breast-conserving treatment (BCT), and does not confer a survival disadvantage compared with standard adjuvant chemotherapy. In addition, the pathological response of primary breast tumors to neoadjuvant chemotherapy appears to be a surrogate marker for patient outcome. In our series, during the period from May 1995 to December 2000, 86 patients with tumors between 3.1 and 6.0 cm in diameter received epirubicin-based neoadjuvant chemotherapy. There were 55 (64.0%) responders and ultimately 64 patients (74.4%) were treated with BCT. The margin positive rate was 14.1% (9/64), similar to the rate after BCT for early-stage breast cancers, the largest diameter of which was smaller than 3 cm. At a median follow-up of 30 months, only 3 patients in the BCT group have developed local recurrence; the local recurrence rate appears to be comparable to that after BCT for early stage breast cancers. Long term follow-up is required, however, to establish whether this procedure is a safe alternative to mastectomy for patients with large breast cancers.

引用

页码：20 / 25

页数：5

共 28 条

[1]

Fisher B., Bryant J., Wolmark N., Mamounas E., Brown A., Fisher E.R., Wickerham D.L., Begovic M., DeCillis A., Robidoux A., Margolese R.G., Cruz Jr. A.B., Hoehn J.L., Lees A.W., Dimitrov N.V., Bear H.D., Effect of preoperative chemotherapy on the outcome of women with operable breast cancer, Journal of Clinical Oncology, 16, 8, pp. 2672-2685, (1998)

[2]

Calais G., Berger C., Descamps P., Chapet S., Reynaud-Bougnoux A., Body G., Bougnoux P., Lansac J., Le Floch O., Conservative treatment feasibility with induction chemotherapy, surgery, and radiotherapy for patients with breast carcinoma larger than 3 cm, Cancer, 74, 4, pp. 1283-1288, (1994)

[3]

Schwartz G.F., Birchansky C.A., Komarnicky L.T., Mansfield C.M., Cantor R.I., Biermann W.A., Fellin F.M., McFarlane J., Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast, Cancer, 73, 2, pp. 362-369, (1994)

[4]

Veronesi U., Bonadonna G., Zurrida S., Et al., Conservation surgery after primary chemotherapy in large carcinomas of the breast, Ann Surg, 222, pp. 612-618, (1995)

[5]

Touboul E., Lefranc J.-P., Blondon J., Buffat L., Deniaud E., Belkacemi Y., Benmiloud M., Huart J., Laugier A., Schlienger M., Primary chemotherapy and preoperative irradiation for patients with stage II larger than 3 cm or locally advanced non-inflammatory breast cancer, Radiotherapy and Oncology, 42, 3, pp. 219-229, (1997)

[6]

Merajver S.D., Weber B.L., Cody R., Zhang D., Strawderman M., Calzone K.A., LeClaire V., Levin A., Irani J., Halvie M., August D., Wicha M., Lichter A., Pierce L.J., Breast conservation and prolonged chemotherapy for locally advanced breast cancer: The University of Michigan experience, Journal of Clinical Oncology, 15, 8, pp. 2873-2881, (1997)

[7]

Bonadonna G., Valagussa P., Brambilla C., Ferrari L., Moliterni A., Terenziani M., Zambetti M., Primary chemotherapy in operable breast cancer: Eight-year experience at the Milan Cancer Institute, Journal of Clinical Oncology, 16, 1, pp. 93-100, (1998)

[8]

Danforth Jr. D.N., Zujewski J., O'Shaughnessy J., Riseberg D., Steinberg S.M., McAtee N., Noone M., Chow C., Chaudhry U., Lippman M., Jacobson J., Okunieff P., Cowan K.H., Selection of local therapy after neoadjuvant chemotherapy in patients with stage IIIA,B breast cancer, Annals of Surgical Oncology, 5, 2, pp. 150-158, (1998)

[9]

Mauriac L., MacGrogan G., Avril A., Durand M., Floquet A., Debled M., Dilhuydy J.M., Bonichon F., Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: A unicentre randomized trial with a 124-month median follow-up, Annals of Oncology, 10, 1, pp. 47-52, (1999)

[10]

Kuerer H.M., Newman L.A., Smith T.L., Ames F.C., Hunt K.K., Dhingra K., Theriault R.L., Singh G., Binkley S.M., Sneige N., Buchholz T.A., Ross M.I., McNeese M.D., Buzdar A.U., Hortobagyi G.N., Singletary S.E., Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy, Journal of Clinical Oncology, 17, 2, pp. 460-469, (1999)

← 1 2 3 →